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Reversible Connexin 43 Dephosphorylation During Hypoxia
and Reoxygenation Is Linked to Cellular ATP Levels
Mark S. Turner, Guy A. Haywood, Peter Andreka, Lijing You, Patricia E. Martin, W. Howard Evans,
Keith A. Webster, Nanette H. Bishopric
Abstract—Altered gap junction coupling of cardiac myocytes during ischemia may contribute to development of lethal
arrhythmias. The phosphoprotein connexin 43 (Cx43) is the major constituent of gap junctions. Dephosphorylation of
Cx43 and uncoupling of gap junctions occur during ischemia, but the significance of Cx43 phosphorylation in this
setting is unknown. Here we show that Cx43 dephosphorylation in synchronously contracting myocytes during ischemia
is reversible, independent of hypoxia, and closely associated with cellular ATP levels. Cx43 became profoundly
dephosphorylated during hypoxia only when glucose supplies were limited and was completely rephosphorylated within
30 minutes of reoxygenation. Similarly, direct reduction of ATP by various combinations of metabolic inhibitors and
by ouabain was closely paralleled by loss of phosphoCx43 and recovery of phosphoCx43 accompanied restoration of
ATP. Dephosphorylation of Cx43 could not be attributed to hypoxia, acid pH or secreted metabolites, or to
AMP-activated protein kinase; moreover, the process was selective for Cx43 because levels of phospho-extracellular
signal regulated kinase (ERK)1/2 were increased throughout. Rephosphorylation of Cx43 was not dependent on new
protein synthesis, or on activation of protein kinases A or G, ERK1/2, p38 mitogen-activated protein kinase, or Jun
kinase; however, broad-spectrum protein kinase C inhibitors prevented Cx43 rephosphorylation while also sensitizing
myocytes to reoxygenation-mediated cell death. We conclude that Cx43 is reversibly dephosphorylated and rephos-
phorylated during hypoxia and reoxygenation by a novel mechanism that is sensitive to nonlethal fluctuations in cellular
ATP. The role of this regulated phosphorylation in the adaptation to ischemia remains to be determined. (Circ Res.
2004;95:726-733.)
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Altered electrical coupling of cardiac myocytes is widelyassumed to promote the development of lethal arrhyth-
mias during myocardial infarction. Electrical coupling in
excitable tissues is mediated by gap junctions, plasma mem-
brane intercellular channels that underpin synchronous elec-
trical activation, and coordination of cardiac myocyte con-
traction. Connexins, the major protein components of gap
junctions, range from 26 to 57 kDa in size; most cell types
express at least 1 connexin isoform.1,2 Mammalian ventricu-
lar gap junctions contain predominantly 43 kDa connexin
(Cx43); atrial and conduction tissue express additional iso-
forms.3–5 Cx43 is essential for normal electrical conduction in
the heart; mice with cardiac-restricted inactivation of Cx43
exhibit slower ventricular conduction and experience lethal
arrhythmias,6–8 and heterozygous deficiency of Cx43 predis-
poses mice to arrhythmia under ischemic stress.9 Cx43 may
also play a role in transmission of cell fate signals during
myocardial ischemia: mice with Cx43 deficiency have
smaller myocardial infarctions after experimental coronary
artery occlusion,10 and administration of the gap junction
blocker heptanol reduces infarct size in ischemic pig and
rabbit hearts.11 Whether modification of Cx43 itself contrib-
utes to the outcome of myocardial infarction remains to be
defined.
Under normal conditions, myocardial Cx43 is highly phos-
phorylated at multiple carboxy-terminal serine and threonine
residues. However, neither the effectors nor the physiological
significance of Cx43 phosphorylation have been fully re-
solved. Recently, using a Langendorff model of global
cardiac ischemia, Beardslee et al demonstrated a fall in
phosphorylated Cx43 (phosphoCx43), accumulation of non-
phosphorylated Cx43 (dephosphoCx43), and loss of gap
junction coupling;12 loss of phosphoCx43 correlated with
inability of the myocardium to recover contractility after
ischemia. The mechanism for dephosphorylation was not
identified, although hypoxia, build-up of toxic metabolites,
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and ATP depletion were suggested as possible factors. In
support of this view, Vera et al reported a close correlation
between ATP levels and gap junction coupling in astrocytes as
measured by Lucifer yellow dye transfer.13 Metabolic inhibition
can induce Cx43 dephosphorylation;14 and prolonged acidifica-
tion causes Cx43 membrane dissociation and internalization.15
None of these studies determined whether Cx43 dephosphory-
lation and gap junction uncoupling was a result of catastrophic
cell damage or a regulated and reversible process. Similarly, the
protein kinases controlling the phosphorylation of Cx43 have not
been fully characterized but may include protein kinase C
(PKC),16,17 protein kinase A (PKA),18 and extracellular signal–
regulated kinases (ERKs).19
To address these questions, we studied the individual contri-
butions of hypoxia, extracellular factors, glucose, and ATP
depletion to ischemic dephosphorylation of Cx43 in a well-
defined cardiac myocyte model of hypoxia and ischemia. We
show here that the phosphorylation state of Cx43 is reversibly
regulated by specific mechanisms that are independent of hyp-
oxia but are tightly linked to cellular levels of ATP.
Materials and Methods
Reagents
PD98059, SB203850, bisindolmaleimide, chelerythrine, antimycin A,
potassium cyanide, deoxyglucose (DOG), phorbol 12-myristate 13-
acetate (PMA), KT5720, KT5823, staurosporine, cycloheximide,
5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR),
brefeldin A, okadaic acid, and FK506 were from Calbiochem and were
used at established effective concentrations. The recombinant adenovi-
rus encoding a dominant-negative Jun kinase mutant was described
previously.20,21 Dr Daria Mochly-Rosen (Stanford University, Stanford,
Calif) generously provided peptide inhibitors and activators of PKC 
and  isoforms.
Cell Culture
Cardiac myocytes were prepared from 1- to 3-day-old neonatal rat
hearts as described previously,22 maintained in minimal essential
medium (MEM)5% FCS for 3 days to allow formation of synchro-
nously contracting monolayers, and then transferred to defined
serum-free medium (MEMtransferrininsulinvitamin B12) for
the duration of the experiments. Some cells were maintained in high
glucose (HG) media (3 g/L glucose) at a volume of 2 mL per 106
cells and replenished with fresh hypoxic media after 10 hours. All
other experiments used low glucose (LG) media (0.2 g/L glucose); 1
mL of this medium was added per 106 cells.
Cells were rendered hypoxic in an environmental chamber con-
taining 0.5% O2, 5% CO2 (balance N2) with access via gas-tight
sleeves as described previously.23 Control cells were maintained in
ambient (21%) O2 and 5% CO2. Reagents were added at defined
times before or during hypoxia/ischemia, or included in reoxygena-
tion media as required. Myocyte contractility was monitored using a
dedicated Nikon IM microscope housed in the chamber.
Immunoblot Analysis
Cells were washed in ice-cold PBS, pH 7.4, and harvested in 1%
SDS, 1 mmol/L dithiothreitol, 1 mmol/L sodium vanadate, protease
inhibitors, and 1 mmol/L phenylmethylsulfonyl fluoride or phenyl-
methanesulfonyl fluoride, and disrupted by sonication. Protein con-
centrations were determined using a BioRad detergent-compatible
assay. Western blots were prepared, probed, and imaged as described
previously21 using either a mouse monoclonal antibody against
dephosphoCx43 or a rabbit polyclonal antibody recognizing phos-
phoCx43 and dephosphoCx43 (both from Zymed). Equal blot
transfer was confirmed by Ponceau S staining. Primary monoclonal
and polyclonal antibodies against phospho-extracellular- regulated
kinase-1/2 were obtained from Cell Signaling and Promega, respec-
tively. The sum of the densities of Cx43-specific bands in the control
sample was arbitrarily set to 1.0, and the density of individual
phosphorylated and nonphosphorylated bands was normalized to this
value.
ATP Assay
Cell samples were washed in ice-cold PBS and harvested on ice in
5% trichloroacetic acid. ATP was measured in cell lysates using a
luminescence-based assay as described.24 Values were normalized to
lysate protein concentrations.
Statistics
ANOVA with multiple column comparisons and unpaired Student t
tests where appropriate were performed as indicated using InStat
2.00 software for Macintosh (GraphPad). Data are expressed
as meanSEM.
Results
Effects of Hypoxia, Ouabain, and Metabolic
Inhibition on Synchronous Myocyte Contraction
Synchronous beating is a sensitive indicator of normal gap
junction coupling in cardiac myocyte cultures. During hypoxia,
myocytes in HG media (3.0 g/L) continued to beat rapidly and
synchronously for 20 hours, consistent with previous findings
from our laboratory that myocyte ATP levels and viability can
be maintained by induction of glycolysis even under conditions
of severe hypoxia.25 In contrast, hypoxic cells in LG media (0.2
g/L) stopped beating within 2 hours (data not shown). As in our
earlier reports, cessation of beating was preceded by a gradual
loss of contractile amplitude rather than by deceleration.25 Loss
of contractility was reversible up to 8 hours after hypoxia onset,
and synchronous beating resumed within 30 minutes of reoxy-
genation. Previous studies have shown that myocardial gap
junction communication is reduced by ouabain, a positive
inotropic agent and Na/K ATPase inhibitor.26 Consistent with
this, normoxic cells stopped contracting within 1 hour in the
presence of ouabain and resumed beating within 60 minutes of
washout. Metabolic inhibition with iodoacetate alone or in
combination with KCN, or with antimycin A (10 mol/L) plus
DOG caused loss of beating within 30 minutes that was
irreversible by 90 minutes. A combination of DOG and KCN in
LG medium caused complete but reversible cessation of beating
between 4 and 8 hours after treatment (data not shown).
Glucose Depletion Leads to Dephosphorylation
of Cx43
We wished to determine whether hypoxia itself, as opposed to
energy depletion, was the stimulus for Cx43 dephosphoryla-
tion. Cells were therefore rendered hypoxic in HG media,
with refeeding every 12 hours to prevent depletion of glyco-
lytic substrates and accumulation of waste products. Under
HG hypoxia, the relative predominance of phosphoCx43 was
maintained, although the absolute amount of both phos-
phoCx43 and dephosphoCx43 increased significantly over
time (Figure 1A; 1.65-fold and 1.89-fold at 8 and 20 hours,
respectively; P0.01 for both). Total Cx43 levels returned
toward baseline levels within 4 hours of reoxygenation
(1.120.15-fold of control; P0.01).
In contrast, cells in LG media exhibited loss of phos-
phoCx436 hours of hypoxia, with a corresponding increase in
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Figure 1. Cx43 phosphorylation during hypoxia, metabolic inhibition and simulated ischemia and simulated ischemia. A, Preservation of
phosho-connexin43 (phosphoCx43) in hypoxia. Black bars indicate phosphoCx43; gray bars, dephosphoCx43; Air, aerobic cells; Reox,
reoxygenation (n5; *P0.01 for comparison with Air and Reox samples). Cells were cultured in 0.5% oxygen as described in Meth-
ods, with regular glucose supplementation. B, Reversible dephosphorylation of phosphoCx43 during hypoxia with glucose depletion.
Cells were cultured as above except that starting media glucose concentration was 0.2 g/L and was not replenished. Cell lysates were
harvested and subjected to Western analysis using either a polyclonal Cx43 antibody recognizing all Cx43 species (center) or a mono-
clonal antibody specific for dephosphoCx43 (bottom; n22; *P0.01 for comparison with Air and Reox samples; **P0.0001 vs Air). C,
Lack of effect of phosphatase inhibitors. Okadaic acid (10, 20, and 100 nM) and calyculin A (20 nM) are shown in a representative
Western blot (n5; *P0.01). Additional data are presented in the table. D, Maintenance of phospho-ERK levels in LG hypoxia. The
same cell lysates shown in B were analyzed on Western blots probed with an antibody specific for phosphoERK (see Methods; n6;
*P0.05 vs control). In all experiments, synchronously contracting monolayers of cardiac myocytes were cultured under hypoxia with or
without glucose supplementation or in ambient oxygen as described in Methods. Cells were harvested at the indicated time points after
treatment, after hypoxia, or after hypoxia and reoxygenation.
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dephosphoCx43 (Figure 1B). By 8 hours of hypoxia (6 hours
after beating ceased), phosphoCx43 had fallen from
75.820.0% to 27.34.40% of total Cx43 (P0.0001), with a
corresponding rise in dephosphoCx43 from 25.33.3% to
72.76.6% of the total (P0.01). Hypoxic dephosphorylation
of Cx43 occurred despite inhibition of protein phosphatases
(PPs) 1A and 2A using okadaic acid and calyculin A (Figure
1C), although both compounds increased the proportion of
phosphoCx43 in aerobic samples. Inhibition of calcineurin also
was without effect (data not shown). AICAR (0.5 mmol/L), a
direct activator of AMP-activated protein kinase, had no effect
on Cx43 phosphorylation in normoxic cells at time points
between 30 minutes and 4 hours (data not shown). Neither Cx43
phosphorylation nor contractile activity was affected by passive
transfer of medium from LG hypoxia cells (data not shown).
Within 30 minutes of reoxygenation, phosphoCx43 rose to
50.54.4% of total Cx43, and dephosphoCx43 decreased to
21.23.3%, both P0.01 compared with hypoxia (Figure 1B),
associated with the return of synchronous beating. In contrast,
phosphoERK1/2 increased dramatically during LG hypoxia in
the same cells (Figure 1D), indicating that the 2 proteins are
subject to distinct ischemia-associated regulatory signals.
Cx43 Phosphorylation Correlates With Cellular
ATP Levels
To explore the relationship between high-energy phosphate
availability and Cx43 phosphorylation, we measured ATP
Figure 2. Cx43 phosphorylation correlates with cellular ATP lev-
els. A, Decline of ATP levels during LG and HG hypoxia, meta-
bolic inhibition, and ouabain treatment. Cardiac myocytes were
cultured in media containing HG (dotted line) or LG (solid line)
glucose concentrations and subjected to hypoxia. Myocytes in
LG media were treated with iodoacetate 0.3 mmol/L, KCN
1 mmol/L, or ouabain 1 mmol/L as described in Methods. ATP
levels recovered within 30 minutes of reoxygenation of LG
hypoxic cells (arrow) and within 1 hour after washout of
ouabain. n6; for ouabain, P0.01 vs control at 30 and 90 min-
utes; for LG hypoxia, P0.001 at 6 and 8 hours. B, Dephos-
phorylation of phosphoCx43 by ouabain and metabolic inhibi-
tors. Cells were maintained in ambient oxygen and treated for
90 with 1 mmol/L KCN, 0.3 mmol/L iodoacetate (iodo), or
1 mmol/L ouabain, harvested, and analyzed as in Figure 1A. In
some samples, ouabain was removed from the media and cells
were incubated for a further 60 (washout, arrow). Representa-
tive Western blots are shown. (n6; *P0.01 vs control;
**P0.05 vs 1.0-hour samples). C, Reversible dephosphorylation
of phosphoCx43 by DOG and KCN. After the indicated incuba-
tion times in DOGKCN (4 mmol/L and 2 mmol/L, respectively),
samples were washed and placed in fresh LG media for an
additional 2 hours (washout, arrows). Western analysis was
conducted as above (data are representative of 3 separate
experiments). *P0.05.
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levels in cells under each condition. As predicted, ATP
decreased only slightly during HG hypoxia (Figure 2A). In
LG hypoxia, ATP remained stable for 4 hours (and at least 2
hours after cessation of beating) but fell to 50% of control
between 6 and 8 hours and rose again with reoxygenation
(Figure 2A), closely paralleling the time course of Cx43
dephosphorylation and recovery.
We then manipulated intracellular ATP levels with
ouabain, which increases ATP consumption in contracting
myocytes,27 or with combinations of antimycin A, iodoac-
etate, KCN, and DOG, which inhibit ATP production.
Ouabain induced a 70% fall in ATP levels and a significant
dephosphorylation of Cx43 (compare Figure 2A and 2B, top
right). Exposure to iodoacetate, antimycin ADOG, or
KCNiodoacetate caused loss of phosphoCx43 within 90
minutes (Figure 2B; data not shown) together with loss of
contractile activity. KCN by itself caused only a small fall in
ATP, and no reduction in phosphoCx43 (compare Figure 2A
and 2B, top left, lane 2), suggesting that loss of ATP and not
the presence of specific chemical compounds was a key
signal for Cx43 dephosphorylation. Although the effects of
iodoacetate and antimycin A were irreversible (Figure 2A;
data not shown), cells exposed to ouabain (Figure 2A and 2B)
or DOGKCN (Figure 2C) resumed beating after 1 to 2
hours of washout, accompanied by a partial recovery of ATP
and near-complete recovery of phosphoCx43. These findings
suggest that contractility and phosphoCx43 are supported
above a threshold of 50% of basal ATP levels.
Recovery of PhosphoCx43 Is Not Attributable to
De Novo Synthesis and Is Resistant to Inhibition
of Mitogen-Activated Protein Kinases A and G
The recovery of phosphoCx43 after reoxygenation could arise from
de novo synthesis and subsequent phosphorylation of Cx43 or from
the rephosphorylation of existing protein. However, blocking new
protein synthesis with 30 exposure to cycloheximide had no effect
on the recovery of phosphoCx43 during reoxygenation (Table). To
identify the kinases responsible for the rephosphorylation of Cx43,
we tested a series of selective inhibitors and dominant-negative
mutants, the results of which are summarized in the table. The MAP
kinases (p38, ERK, and c-Jun N-terminal kinase [JNK]) are acti-
vated by hypoxia and reoxygenation20,28 (Figure 1D) and therefore
were obvious candidates for the rephosphorylation of Cx43; more-
over, JNK activation has been linked to loss of Cx43 during cell
stress.29 However, neither PD98059 and SB203850, selective in-
hibitors of ERK and p38 mitogen-activated protein kinase (MAPK),
respectively, nor an adenovirus expressing a dominant-negative
mutant of JNK shown previously to eliminate reoxygenation-
mediated JNK activation,20 had any effect on Cx43 abundance or
phosphorylation whether in the presence or absence of hypoxia,
despite essentially complete loss of kinase activity (Table; data not
shown). Likewise, inhibition of protein kinases A and G with
maximally effective concentrations of the selective inhibitors
KT5720 and KT5823, respectively,21,30 also failed to impair the
reoxygenation-mediated recovery of phosphoCx43 (Table).
PhosphoCx43 Recovery Is Blocked by
Broad-Spectrum PKC Inhibition
PKC has been implicated in phosphorylation of Cx43.31 Inhibi-
tion of PKC with bisindolmaleimide or chelerythrine, and with
the broad-spectrum protein kinase inhibitor staurosporine, pre-
vented recovery of phosphoCx43 (Table; Figure 3A; data not
shown). Interestingly, broad-spectrum PKC inhibition by either
compound also caused strong enhancement of reoxygenation-
mediated cell death, preventing the recovery of cellular ATP
levels (data not shown), suggesting increased susceptibility to
mitochondrial oxidative damage. In contrast, in normoxic cells,
an equivalent 60 exposure to chelerythrine had no effect on
survival, ATP levels, or phosphoCx43 (Figure 3A, lane 4; data
not shown). Because PKC isoforms  and  have been impli-
Loss and Recovery of Phospho-Cx43 During Ischemia and Reperfusion
Conditions Target
Control Inhibitor
Air HX HXReox Air HX HXReox
P NP P NP P NP P NP P NP P NP
Cycloheximide Protein synthesis 666 346 283 508 404 293 554 297 244 417 4310 263
Brefeldin 5mol/L Golgi processing 703 303 295 7313 626 415 6519 377 327 5226 655 465
SB203850 5
mol/L
p38MAPK 7811 2211 2012 444 526 2512 674.9 332.1 226.1 519.4 6410 343.0
PD98059 50
mol/L
ERK 941.4 6.31.4 1620 3518 6812 9.55.2 1132.0 110.8 1010 5921 9518 3913
Ad-dnJNK1 Jun kinase 671.5 331.5 8.74.1 273.6 4419 254.3 672.8 273.0 5.42.6 332.7 4811 222.8
KT5720 100
nmol/L
PKA 6116 3916 2820 4919 606.6 3911 644.9 365.6 2013 5212 485.8 352.8
KT5823 40 mol/L PKG 703.2 303.2 2212 435.0 5010 352.1 726.1 320.1 208.4 466.7 5317 353.6
Bisindomaleimide 5
mol/L
PKC 772.3 232.3 172.7 6021 4310 239.5 6416 2020 154.8 5322 259.8 2711
Chelerythrine 5
mol/L
PKC 708.3 308.3 169.1 422.9 455.8 235.9 694.8 218.0 169.3 402.8 187.8 199.3
Staurosporine 10
mol/L
Multiple PKs 626.5 386.5 3019 612.3 6614 424.1 906.1 461.5 1811 518.4 2615 2618
Effect of inhibitors of protein synthesis, processing, and protein kinases. NP indicates nonphosphorylated connexin; P, total phospho-Cx43.
Data were obtained by densitometry of 3–6 individual experiments. Data points from each experimental condition were normalized and expressed as a percentage
of control PNP Cx43 performed in parallel.
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cated in the cell response to anoxia and reoxygenation in cardiac
myocytes,32 we also used Tat-conjugated peptide agonists and
antagonists of these isoforms in the same system (Figure 3B,
bottom). Inhibitory - or -specific PKC peptides did not block
recovery of phosphoCx43 to control levels on reoxygenation
(Figure 3B, lanes 5 and 6). Furthermore, a PKC -specific
peptide agonist failed to reverse Cx43 dephosphorylation in
hypoxic, glucose-depleted myocytes (Figure 3B, lane 4). None
of the peptide reagents exhibited cytotoxicity under these exper-
imental conditions. Finally, direct activation of PKC by PMA
(10 nM, 15) failed to phosphorylate Cx43 in hypoxic cells
(Figure 3C, lanes and 5), although PMA did appear to eliminate
basal dephosphoCx43 in aerobic cells (Figure 3C, lane 3),
suggesting that additional factors are required to phosphorylate
Cx43 when ATP levels are compromised.
Discussion
Ischemia is a complex insult, comprising hypoxia, acidosis,
build-up of toxic metabolites, and ultimately ATP depletion. We
show here that Cx43 dephosphorylation is not a consequence of
irreversible myocardial damage but is a regulated and reversible
process that is exquisitely sensitive to ATP levels. Neither hypoxia,
per se, nor soluble metabolite accumulation accounted for Cx43
dephosphorylation, nor was it a passive consequence of high-energy
phosphate depletion because ERK phosphorylation increased under
the same conditions. Instead, the mechanisms regulating Cx43
phosphorylation appear to be selective and closely linked to the
decline and recovery of cellular ATP levels below a critical
threshold. Although such a relationship has been postulated,13 the
existence and significance of a specific correlation between con-
nexin phosphorylation and ATP levels have not been established
previously.
Gap junction activity is regulated at multiple levels, includ-
ing Cx43 expression, degradation, and phosphorylation.15,33,34
Basal phosphorylation–dephosphorylation cycles regulating
phosphoCx43 content are largely dependent on PP1 activi-
ty,35 and PP1 has also been reported to be involved in the
dephosphorylation of Cx43 during ischemia.36 The functional
significance and specific molecular targets of phosphoryla-
tion in the gap junction are not clear, although electrical
Figure 3. Effect of inhibition of PKC on rephosphorylation of Cx43 after reoxygenation. A, The broad spectrum PKC inhibitor cheleryth-
rine blocks recovery of phosphoCx43 after reoxygenation. Chelerythrine (5 mol/L) was added 1 hour before harvesting and 30 before
reoxygenation. n4; *P0.01 vs hypoxia 8-hour sample. Similar results were obtained with bisindolmaleimide and staurosporine
(Table). B, Subtype-selective modulation of PKC- and - does not affect Cx43 dephosphorylation or recovery. Western blot shown is
representative of 3 different experiments in which similar data were obtained. TAT-conjugated peptide activators and inhibitors of PKC
isoforms were provided by Dr D. Mochly-Rosen and used as described in Dorn et al.32 In brief, stock solutions of TAT-conjugated pep-
tide activators and inhibitors of PKC- or -, or their vehicle (water; final concentration each 1 mol/L) were added directly to the
hypoxic cell cultures 30 minutes before reoxygenation and included in the normoxic media added at reoxygenation. C, PKC cannot
prevent hypoxic dephosphorylation of Cx43. Cardiac myocytes were cultured at ambient O2 tensions (air) or in hypoxia (H) for 8 hours.
Either 10 nM PMA or its vehicle was added to cultures for 15 before harvesting. Chart summarizes data from 3 experiments.
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conductance and dye permeability may be affected.37–40
Surprisingly, metabolic dephosphorylation of Cx43 did not
require PP1 because it was insensitive to calyculin A and
okadaic acid in our system, although calyculin A and higher
concentrations of okadaic acid reduced the relative amount of
dephosphoCx43 in control cells. We also considered the
possibility that AMP kinase, an ATP sensor, could be
involved in this regulatory dephosphorylation indirectly via
activation of unknown phosphatases; however, direct activa-
tion of AMP kinase by AICAR did not induce Cx43 dephos-
phorylation (data not shown).
The protein kinase involved in Cx43 rephosphorylation
also remains to be identified. The lack of a requirement for
new protein synthesis and the presence of significant amounts
of dephosphoCx43 at areas of cell–cell contact12 (data not
shown) suggests that this protein kinase is likely to reside in
the vicinity of myocyte plasma membrane gap junctions and
to phosphorylate pre-existing dephosphoCx43. The Western
analyses shown here do not shed light on specific residues
regulated by ATP or provide information about which kinases
may be mediating this regulation. Despite previous hints of
ERK involvement19 and the known activation of MAPKs
during ischemia reperfusion,41 our results indicate that no
single one of the classical MAPKs is likely to be involved.
Alternatively, Cx43 rephosphorylation may rely on multiple
protein kinases.18,42
PKC has also been implicated in Cx43 phosphoryla-
tion,17,31,43 although it is not clear whether this is a direct or
indirect effect.43 Our data exclude a direct role for either
PKC- or PKC- isoforms in the rephosphorylation of Cx43
after hypoxia, suggesting that this represents a distinct phys-
iologic signal pathway to that reported previously for fibro-
blast growth factor 2 stimulation.17 However, our data are
consistent with a role for the classical PKC pathway in
phosphorylation of Cx43. In our system, the direct effects of
PKC on Cx43 phosphorylation may be less important than its
secondary effects on reoxygenation damage, mitochondrial
ATP production, and cell survival; significantly, direct acti-
vation of PKC did not restore Cx43 phosphorylation under
conditions of ATP depletion, and broad-spectrum PKC inhib-
itors prevented Cx43 rephosphorylation but also promoted
reoxygenation-mediated cell death. We propose that PKC
may be required for the resumption of mitochondrial ATP
production after ischemic stress, and thus indirectly permis-
sive for recovery of phosphoCx43. Further studies are re-
quired to identify the direct ATP sensor.
Dephosphorylation of phosphoCx43 could play a role in
the cellular response to ischemia through effects on the
transmission of cell fate signals. Cx43-deficient and heptanol-
treated hearts are resistant to ischemia reperfusion damage,
suggesting that gap junctions may communicate death signals
between damaged and intact cells10,11 or lead to loss of ATP
and death through opening of membrane hemichannels.44,45
On the other hand, loss of gap junction coupling also
eliminates the protective effects of ischemic precondition-
ing.46,47 Cx43 phosphorylation may affect cell survival and
electrical activity differently;48 dephosphorylation of Cx43
can impair transmission of chemical signals through gap
junctions while maintaining electrical coupling.49 Differential
regulation of electrical and metabolic coupling also occurs in
response to voltage gating50 and may represent a protective
adaptation.51 Further work will be required to determine the
influence of regulated dephosphorylation of Cx43 on the
pathophysiology of myocardial ischemia.
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